Skip to main content

Generics

  • Colonial Life: Three healthcare trends that can impact retail pharmacy in 2012

    COLUMBIA, S.C. — Colonial Life and Accident Insurance last week released its top five trends and predictions for health care in 2012 — three of which may have some direct impact on retail pharmacy.

  • Watson launches generic painkiller

    PARSIPPANY, N.J. — Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.

    Watson announced the Food and Drug Administration approval and launch of morphine sulfate extended-release capsules.

    The drug is a generic version of Actavis' Kadian, which had sales of about $275 million during the 12-month period ended in September, according to IMS Health.

  • Pawlenty and ‘who’s who’ of retail pharmacy headline 13th annual Issues Summit

    NEW YORK — CVS/pharmacy. Rite Aid. Walgreens. Sam’s Club. Ahold. H-E-B. The Katz Group. Giant Eagle. Good Neighbor. Health Mart. The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, here at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing.

  • Appeals court rejects Teva request to stop Watson from selling generic Seasonique

    PARSIPPANY, N.J. — An appeals court has thrown out an attempt by Teva Pharmaceutical Industries to stop Watson Pharmaceuticals from selling a generic contraceptive, Watson said.

    The U.S. Court of Appeals for the Federal Circuit affirmed a lower court's June 16 decision to deny Duramed Pharmaceuticals' request for an injunction that would stop Watson from selling a generic version of Seasonique (levonorgestrel and ethinyl estradiol [0.15 mg/0.03 mg] and ethinyl estradiol [0.01 mg]). Duramed originally was a subsidiary of Barr Pharmaceuticals, which Teva acquired in 2008.

  • Watson files for approval of generic dementia treatment

    PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging three of Swiss drug maker Novartis' patents on a drug used to treat dementia, Watson said.

    The company said subsidiary Watson Labs had filed for approval generic rivastigmine transdermal system patches in the 4.6-mg and 9.5-mg strengths, both designed to last for 24 hours, with the Food and Drug Administration. The patches are used to treat mild to moderate dementia associated with Alzheimer's or Parkinson's disease.

  • Surveys: HSA utilization on the rise

    DALLAS — Employers and consumers alike are adopting health savings accounts as a viable way to manage their healthcare costs without compromising care, according to two national surveys released Thursday.

  • Mylan acquires rights to Pfizer's inhaler technology

    PITTSBURGH — Generic drug maker Mylan has bought rights to a drug delivery platform made by Pfizer that will allow it to make generic versions of two GlaxoSmithKline respiratory drugs, Mylan said Wednesday.

  • Safeway flu survey: Only half of Americans will get flu shot this year

    PLEASANTON, Calif. — Nearly two-thirds of Americans believe flu shots prevent the flu, but only half plan to get the shot this year, according to the "Safeway Seasonal Wellness Survey," conducted by Kelton Research.

    This is especially surprising, given that 89% said getting a flu shot is “as important” (50%) or “more important” (39%) than it was five years ago.

X
This ad will auto-close in 10 seconds